Ethan Taylor  Yeni makale yazdı
1 w ·çevirmek

Ozempic’s Expanded Approval Propels Novo Nordisk to the Top of GLP-1 Market | #chronic Kidney Disease # chronic kidney disease market # GLP-1 receptor # GLP-1R/GIPR agonist

Ozempic’s Expanded Approval Propels Novo Nordisk to the Top of GLP-1 Market

Ozempic’s Expanded Approval Propels Novo Nordisk to the Top of GLP-1 Market

Novo Nordisk Strengthens Its GLP-1 Leadership with Ozempic’s Latest Approval